Yes. Linezolid is active against Mycobacterium tuberculosis and is used in combination regimens for multidrug-resistant and extensively drug‑resistant TB. It inhibits bacterial protein synthesis but isn’t a first‑line drug because of significant toxicity. Prolonged use can cause myelosuppression, peripheral/optic neuropathy, lactic acidosis and drug interactions, so treatment is reserved for resistant cases under specialist supervision.

Pulmonary TB is treated with first‑line antibiotics: isoniazid, rifampicin (rifampin), pyrazinamide and ethambutol, usually given in a 2‑month intensive phase followed by 4 months of isoniazid plus rifampicin. Latent TB may use isoniazid or rifampicin regimens. Drug‑resistant TB requires specialist second‑line drugs such as fluoroquinolones, amikacin, linezolid, bedaquiline and others.

Linezolid is effective against drug-resistant tuberculosis and is used as part of combination regimens for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. It helps suppress Mycobacterium tuberculosis when other drugs fail, but it isn’t a routine first-line agent. Long-term use risks include bone marrow suppression, neuropathy and lactic acidosis, so treatment requires specialist supervision and regular monitoring.

Linezolid is used in multidrug-resistant TB regimens and is usually given for at least six months; treatment duration is individualized and often continues six to twelve months or longer depending on clinical response, culture conversion and tolerability. Because of risks such as peripheral neuropathy and bone marrow suppression, therapy requires close monitoring with dose adjustment or discontinuation if toxicities develop.

Isoniazid and rifampicin are the principal bactericidal antibiotics used to kill Mycobacterium tuberculosis. Pyrazinamide has bactericidal activity in acidic environments, while ethambutol is mainly bacteriostatic. Treatment is given as a combination regimen (commonly isoniazid, rifampicin, pyrazinamide and ethambutol initially) for at least six months to prevent resistance; some strains need additional or alternative drugs.

Yes. Linezolid has activity against Mycobacterium tuberculosis and is used in pulmonary TB mainly for multidrug‑resistant (MDR/XDR) cases as part of a combination regimen. It is not a first‑line drug because of limited long‑term evidence and serious toxicities (bone‑marrow suppression, peripheral/optic neuropathy, lactic acidosis). Use requires specialist oversight, dose adjustment and regular monitoring.